{
    "symbol": "HALO",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-08 19:00:31",
    "content": " Total quarterly revenue was $209 million, also a record, with strong growth of 80% over same period prior year. On the third quarter update goal, Janssen\u00e2\u0080\u0099s parent Johnson & Johnson reported the worldwide sales of DARZALEX, including both the IT and subcutaneous forms of $2 billion, an increase of more than 38% year-over-year on an operational basis. On the recent third quarter call, organic noted strong position in patient demand for Vyvgart and reported total quarterly net product revenues of $131 million with 2,000 patients on treatment. Total revenue for the third quarter was $209 million, compared to $115.8 million in the prior year period. Royalty revenue for the third quarter was $99.6 million, an increase of 70% compared to $58.6 million in the prior year period. As disclosed in our second quarter earnings call, we expect total revenues of $655 million, $685 million for the full year 2022. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}